Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Novavax

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 1.5K

Market Cap: $1.7B

Website

Introduction: Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Clinical Trials

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Phase 4

Active, not recruiting

Conditions: COVID-19
Vaccine-Preventable Diseases
SARS CoV 2 Infection

Interventions: Biological: Pfizer mRNA COVID-19 vaccine

First Posted Date: 2024-10-09

Last Posted Date: 2025-03-10

Lead Sponsor: Novavax

Target Recruit Count: 660

Registration Number: NCT06633835

Locations: 🇺🇸
University of Utah School of Medicine, Salt Lake City, Utah, United States

Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine

Phase 2

Withdrawn

Conditions: COVID-19

Interventions: Biological: tNIV 1 and Matrix-M Adjuvant

First Posted Date: 2024-07-03

Last Posted Date: 2025-03-11

Lead Sponsor: Novavax

Target Recruit Count: 1200

Registration Number: NCT06485752

Lot Consistency Study of COVID-19 and Influenza Combination Vaccine

Phase 2

Withdrawn

Conditions: COVID-19
Influenza

Interventions: Biological: coformulated CIC Vaccine
Biological: Fluzone HD trivalent

First Posted Date: 2024-07-01

Last Posted Date: 2025-03-11

Lead Sponsor: Novavax

Target Recruit Count: 1925

Registration Number: NCT06482359

A Strain Change Study for SARS-CoV-2 rS Vaccines

Phase 3

Active, not recruiting

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Interventions: Biological: NVX-CoV2705 Vaccine

First Posted Date: 2024-05-10

Last Posted Date: 2025-02-21

Lead Sponsor: Novavax

Target Recruit Count: 60

Registration Number: NCT06409663

Locations: 🇺🇸
Foothills Research Center - CCT Research, Phoenix, Arizona, United States
🇺🇸
Benchmark Research, Austin, Texas, United States

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Phase 3

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant
Biological: Novavax COVID-19 Vaccine
Biological: tNIV Vaccine
Biological: Fluzone High Dose

First Posted Date: 2024-03-04

Last Posted Date: 2025-04-15

Lead Sponsor: Novavax

Target Recruit Count: 9320

Registration Number: NCT06291857

Locations: 🇦🇺
Paratus Clinical Research - Canberra - PPDS, Bruce, Australian Capital Territory, Australia
🇦🇺
Momentum Wellers, Wellers Hill, Brisbane, Australia
🇦🇺
Paratus Clinical Research - Western Sydney - PPDS, Blacktown, New South Wales, Australia

and more 55 locations

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: XBB.1.5 Vaccine (single dose)
Biological: XBB.1.5 Vaccine (Booster)

First Posted Date: 2023-08-03

Last Posted Date: 2024-05-30

Lead Sponsor: Novavax

Target Recruit Count: 660

Registration Number: NCT05975060

Locations: 🇺🇸
AMR, Knoxville, Tennessee, United States
🇺🇸
Benchmark Research, Fort Worth, Texas, United States
🇺🇸
Lynn Institute of the Rockies, Colorado Springs, Colorado, United States

and more 16 locations

Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
Biological: Prototype/XBB.1.5 Bivalent Vaccine (5 µg)

First Posted Date: 2023-08-02

Last Posted Date: 2024-12-05

Lead Sponsor: Novavax

Target Recruit Count: 400

Registration Number: NCT05973006

Locations: 🇺🇸
Alfa Medical Research, Davie, Florida, United States
🇺🇸
Westside Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸
ITB Research, Miami, Florida, United States

and more 13 locations

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: NVX-CoV2601 (5μg)
Biological: NVX-CoV2601(5μg)
Biological: NVX-CoV2601 (35μg)
Biological: NVX-CoV2601(35μg)
Biological: NVX-CoV2601(50μg)
Biological: Bivalent BA.4/5
Biological: NVX-CoV2373 (5μg)

First Posted Date: 2023-06-29

Last Posted Date: 2024-12-13

Lead Sponsor: Novavax

Target Recruit Count: 994

Registration Number: NCT05925127

Locations: 🇺🇸
ARS-Birmingham CRU, Birmingham, Alabama, United States
🇺🇸
Tucson Neuroscience Research, Tucson, Arizona, United States
🇺🇸
Velocity Clinical Research, Banning, Banning, California, United States

and more 37 locations

Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: SARS-CoV-2 rS antigen/Matrix-M Adjuvant
Biological: NVX-CoV2373

First Posted Date: 2023-05-25

Last Posted Date: 2025-06-26

Lead Sponsor: Novavax

Target Recruit Count: 147

Registration Number: NCT05875701

Locations: 🇺🇸
Benchmark Research, Fort Worth, Texas, United States
🇺🇸
Tekton Research, San Antonio, Texas, United States
🇺🇸
Research Your Health, Plano, Texas, United States

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

Phase 2

Completed

Conditions: Influenza
COVID-19

Interventions: Drug: CIC Vaccine with Matrix-M Adjuvant
Drug: qNIV Vaccine with Matrix-M Adjuvant
Drug: SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant
Drug: Influenza Vaccine
Other: Placebo Comparator

First Posted Date: 2022-08-29

Last Posted Date: 2024-07-16

Lead Sponsor: Novavax

Target Recruit Count: 1579

Registration Number: NCT05519839

Locations: 🇦🇺
Paratus Clinical Research - Canberra, Bruce, Australian Capital Territory, Australia
🇦🇺
Paratus Clinical Research - Western Sydney, Blacktown, New South Wales, Australia
🇦🇺
Emeritus Research - Sydney, Botany, New South Wales, Australia

and more 32 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy